## **AMENDMENTS TO THE CLAIMS**

Claims 1-2 (Canceled).

Claim 3 (Previously Presented): An immunogenic composition comprising as an immunogen a long synthetic or recombinant peptide consisting of a MSP-3c peptide (SEQ ID No. 13), or a MSP-3d peptide (SEQ ID No. 14) and combinations of said peptides.

Claim 4 (Previously Presented): A vaccine against malaria comprising the long synthetic or recombinant peptide of Claim 3 and a pharmaceutically acceptable carrier.

Claim 5 (Previously Presented): The immunogenic composition of claim 3, wherein said long synthetic or recombinant peptide further consists of a MSP-3a peptide (SEQ ID No: 11).

Claim 6 (Previously Presented): The immunogenic composition of claim 3, which is formulated for subcutaneous injection.

Claim 7 (Currently Amended): The immunogenic composition of claim 6, comprising between 3 µg and to 100 µg of a long synthetic peptide per injection dose.

Claim 8 (Previously Presented): The immunogenic composition of claim 3, further comprising Alum, or an oil/surfactant adjuvant wherein the oil phase is selected from a non-metabolizable mineral oil, a metabolizable mineral oil or a mixture of the two, as an adjuvant.

Claim 9 (Previously Presented): The vaccine of claim 4, wherein said pharmaceutically acceptable carrier comprises Alum or an oil/surfactant adjuvant wherein the

of entroce goding

Application Serial No. 10/774,602 \*\* Reply to Office Action of March 25, 2005

oil phase is selected from a non-metabolizable mineral oil, a metabolizable mineral oil or a mixture of the two.

Claims 10-24 (Canceled).

Claim 25 (Previously Presented): The vaccine of claim 4, wherein said long synthetic or recombinant peptide further consists of SEQ ID No: 11.

Claim 26 (Previously Presented): The vaccine of claim 4, which is formulated for subcutaneous injection.

Claim 27 (Currently Amended): The vaccine of claim 26, comprising between 3 µg and to 100 µg of a long synthetic peptide per injection dose.

Claim 28 (Currently Amended): An immunogenic composition comprising as an immunogen a long synthetic or recombinant peptide consisting of mixtures eombinations of peptides of a MSP-3b peptide (SEQ ID No: 12), a MSP-3c peptide (SEQ ID No: 13) and a MSP-3d peptide (SEQ ID No: 14).

Claim 29 (Currently Amended): A vaccine against malaria comprising a long synthetic or recombinant peptide consisting of mixtures combinations of peptides of a MSP-3b peptide (SEQ ID No: 12), a MSP-3c peptide (SEQ ID No: 13) and a MSP-3d peptide (SEQ ID No: 14) and a pharmaceutically acceptable carrier.